46.76
price down icon0.68%   -0.32
pre-market  プレマーケット:  46.29   -0.47   -1.01%
loading
前日終値:
$47.08
開ける:
$47.57
24時間の取引高:
2.23M
Relative Volume:
0.55
時価総額:
$112.51B
収益:
$49.41B
当期純損益:
$5.59B
株価収益率:
19.59
EPS:
2.3875
ネットキャッシュフロー:
$8.32B
1週間 パフォーマンス:
-2.36%
1か月 パフォーマンス:
+6.35%
6か月 パフォーマンス:
-2.77%
1年 パフォーマンス:
-5.84%
1日の値動き範囲:
Value
$46.64
$47.59
1週間の範囲:
Value
$46.41
$48.03
52週間の値動き範囲:
Value
$43.32
$55.73

Sanofi Adr Stock (SNY) Company Profile

Name
名前
Sanofi Adr
Name
セクター
Healthcare (1105)
Name
電話
-
Name
住所
-
Name
職員
74,846
Name
Twitter
@sanofi
Name
次回の収益日
2026-04-23
Name
最新のSEC提出書
Name
SNY's Discussions on Twitter

Compare SNY vs LLY, JNJ, ABBV, AZN, MRK

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
SNY icon
SNY
Sanofi Adr
46.76 112.51B 49.41B 5.59B 8.32B 2.3875
LLY icon
LLY
Lilly Eli Co
939.47 839.28B 65.18B 20.64B 5.96B 22.59
JNJ icon
JNJ
Johnson Johnson
238.46 574.36B 94.19B 26.80B 19.70B 11.05
ABBV icon
ABBV
Abbvie Inc
207.94 367.80B 61.16B 4.19B 17.82B 2.3614
AZN icon
AZN
Astrazeneca Plc
204.03 316.42B 58.80B 10.24B 8.98B 3.2788
MRK icon
MRK
Merck Co Inc
121.42 299.89B 64.93B 18.26B 12.36B 7.2751

Sanofi Adr Stock (SNY) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-02-12 ダウングレード BofA Securities Buy → Neutral
2026-01-27 開始されました Citigroup Neutral
2026-01-16 ダウングレード UBS Buy → Neutral
2026-01-06 ダウングレード Barclays Overweight → Equal Weight
2025-12-09 ダウングレード Guggenheim Buy → Neutral
2025-12-08 ダウングレード JP Morgan Overweight → Neutral
2025-09-08 アップグレード Morgan Stanley Equal-Weight → Overweight
2025-09-02 アップグレード Deutsche Bank Hold → Buy
2025-08-08 アップグレード JP Morgan Neutral → Overweight
2025-04-15 開始されました Exane BNP Paribas Outperform
2025-03-21 開始されました Goldman Neutral
2025-01-30 アップグレード Deutsche Bank Sell → Hold
2024-07-26 繰り返されました Argus Buy
2024-01-23 開始されました Morgan Stanley Equal-Weight
2024-01-16 再開されました UBS Buy
2023-12-05 ダウングレード JP Morgan Overweight → Neutral
2023-10-30 ダウングレード Stifel Buy → Hold
2023-09-06 アップグレード Berenberg Hold → Buy
2023-07-14 開始されました HSBC Securities Buy
2023-04-28 ダウングレード Deutsche Bank Hold → Sell
2023-03-27 アップグレード Barclays Equal Weight → Overweight
2022-12-13 再開されました Morgan Stanley Overweight
2022-08-12 アップグレード Deutsche Bank Sell → Hold
2022-08-09 ダウングレード UBS Buy → Neutral
2022-05-23 開始されました SVB Leerink Outperform
2021-09-27 アップグレード SVB Leerink Mkt Perform → Outperform
2021-01-15 開始されました Deutsche Bank Sell
2020-09-29 開始されました Berenberg Hold
2020-03-17 アップグレード Barclays Underweight → Equal Weight
2020-03-11 アップグレード Goldman Neutral → Buy
2020-02-11 開始されました SVB Leerink Mkt Perform
2020-01-06 アップグレード JP Morgan Neutral → Overweight
2019-09-23 アップグレード Guggenheim Neutral → Buy
2019-09-20 アップグレード Morgan Stanley Equal-Weight → Overweight
2019-09-03 開始されました Bernstein Outperform
2019-08-14 アップグレード UBS Neutral → Buy
2018-12-11 アップグレード Jefferies Hold → Buy
2018-11-01 アップグレード Barclays Underweight → Equal Weight
2018-10-09 開始されました Guggenheim Neutral
2018-09-10 アップグレード BofA/Merrill Neutral → Buy
2018-08-10 アップグレード Citigroup Neutral → Buy
2018-03-23 アップグレード Liberum Hold → Buy
2018-01-23 ダウングレード Barclays Equal Weight → Underweight
2017-12-06 ダウングレード BofA/Merrill Buy → Neutral
2017-12-01 ダウングレード Morgan Stanley Overweight → Underweight
2017-11-15 アップグレード Barclays Underweight → Equal Weight
2017-08-30 アップグレード HSBC Securities Reduce → Hold
すべてを表示

Sanofi Adr (SNY) 最新ニュース

pulisher
01:00 AM

Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria - GlobeNewswire Inc.

01:00 AM
pulisher
Apr 10, 2026

SNY Earnings History & Surprises | EPS & Revenue Results | SANOFI-ADR (NASDAQ:SNY) - ChartMill

Apr 10, 2026
pulisher
Apr 07, 2026

Sanofi (SNY) Stock Price, News, Quote & History - Yahoo! Finance Canada

Apr 07, 2026
pulisher
Apr 02, 2026

SNY Stock Price, Quote & Chart | SANOFI-ADR (NASDAQ:SNY) - ChartMill

Apr 02, 2026
pulisher
Mar 31, 2026

Morgan Stanley lowers Sanofi stock price target on FX update - Investing.com UK

Mar 31, 2026
pulisher
Mar 31, 2026

Morgan Stanley lowers Sanofi stock price target on FX update By Investing.com - Investing.com Canada

Mar 31, 2026
pulisher
Mar 27, 2026

AstraZeneca Strengthens Position In COPD Race With Successful Trials - Sahm

Mar 27, 2026
pulisher
Mar 25, 2026

Sanofi ADR (NASDAQ:SNY) Presents a Classic Value Investment Case - ChartMill

Mar 25, 2026
pulisher
Mar 24, 2026

Sanofi S.A. stock faces pressure amid dividend payout and sector headwinds on Euronext Paris - AD HOC NEWS

Mar 24, 2026
pulisher
Mar 21, 2026

Medicare Chief Chris Klomp Optimistic On CDC Director Search As Vaccine Fight Roils Agency— 'We Will Select...' - Sahm

Mar 21, 2026
pulisher
Mar 17, 2026

Federal Judge Flags Legal Flaws In RFK Jr.'s Vaccine Overhaul - Sahm

Mar 17, 2026
pulisher
Mar 11, 2026

Sanofi (NASDAQ:SNY) Emerges as a Top Dividend Stock from Methodical Screening - ChartMill

Mar 11, 2026
pulisher
Mar 10, 2026

Dupixent Leads the Charge for Sanofi's Strong Portfolio in Immunology, Vaccines, and Rare Diseases - Morningstar

Mar 10, 2026
pulisher
Mar 02, 2026

MRNA Stock Gains After CHMP Endorses COVID-19-Influenza Combo Shot - Finviz

Mar 02, 2026
pulisher
Mar 02, 2026

Antibiotics Market - GlobeNewswire Inc.

Mar 02, 2026
pulisher
Mar 01, 2026

Sanofi (SNY) and Regeneron's Dupixent Recommended for EU Approval - Finviz

Mar 01, 2026
pulisher
Feb 27, 2026

Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway - Finviz

Feb 27, 2026
pulisher
Feb 27, 2026

DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus - Finviz

Feb 27, 2026
pulisher
Feb 27, 2026

Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates - Finviz

Feb 27, 2026
pulisher
Feb 26, 2026

How Do Investors Really Feel About Sanofi SA? - Sahm

Feb 26, 2026
pulisher
Feb 25, 2026

CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans - Finviz

Feb 25, 2026
pulisher
Feb 24, 2026

BMRN Beats on Q4 Earnings, to Withdraw Roctavian From Market - Finviz

Feb 24, 2026
pulisher
Feb 23, 2026

Sanofi's (SNY) R&D Track Record Remains Investor Concern, Says BofA - Finviz

Feb 23, 2026
pulisher
Feb 20, 2026

Manuela Buxo To Become Head of Sanofi's (SNY) Specialty Care Global Business Unit - Finviz

Feb 20, 2026
pulisher
Feb 19, 2026

Teva And Sanofi Duvakitug Data Support IBD Pipeline And Growth Story - Sahm

Feb 19, 2026
pulisher
Feb 17, 2026

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease - Sahm

Feb 17, 2026
pulisher
Feb 16, 2026

RIGL Stock Rises 59% in a Year: Time to Buy, Hold or Sell? - Finviz

Feb 16, 2026
pulisher
Feb 13, 2026

SNY Stock Falls After Board Suddenly Makes Leadership Change - Finviz

Feb 13, 2026
pulisher
Feb 12, 2026

Sanofi Pulls the Emergency Brake: What the Hudson Ouster and Garijo Appointment Really Mean for Investors - CTOL Digital Solutions

Feb 12, 2026
pulisher
Feb 11, 2026

Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings? - Finviz

Feb 11, 2026
pulisher
Feb 10, 2026

SNY's Rare Disease Drug Wins FDA Breakthrough and Japan Orphan Status - Finviz

Feb 10, 2026

Sanofi Adr (SNY) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
PFE PFE
$26.92
price down icon 1.10%
NVO NVO
$37.52
price up icon 0.21%
$138.99
price down icon 2.18%
$351.02
price down icon 1.29%
NVS NVS
$154.05
price down icon 0.65%
MRK MRK
$121.42
price down icon 1.03%
大文字化:     |  ボリューム (24 時間):